Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting
Our findings highlight a need for future postmarketing safety and effectiveness studies, especially among survivors of breast cancer and women 65 years and older, who were excluded from the randomized controlled trials.
Authors
- Christine D. Hsu (ORCID: https://orcid.org/0000-0002-8200-5133)
- Abbey B. Berenson (ORCID: https://orcid.org/0000-0002-5007-1080)
- Thao N. Hoang (ORCID: https://orcid.org/0000-0001-8444-0529)
- Rebecca M. Carpenter
- Gwyn Richardson (ORCID: https://orcid.org/0000-0002-9338-8213)
- Victor Adekanmbi
- Fangjian Guo
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Menopause The Journal of The North American Menopause Society
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1097/gme.0000000000002703
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00